Clinical Trials - June 19, 2017
LEO Pharma starts Phase 3 clinical study
LEO Pharma has announced that the first patients have been dosed in a phase 3 clinical study of tralokinumab. Tralokinumab is an investigational human monoclonal antibody that specifically targets the cytokine IL-13, which plays an important role in the development of moderate-to-severe atopic dermatitis. Tralokinumab is not currently licensed in any indication. ECZTRA 1, the first […]
Career choice - April 18, 2017
Principal Professional
As Principal Professional at LEO Pharma, Karina Nymark ensures that trials are run according to all elementary principles. Her role is also to drive the clinical trial team forward and, perhaps most importantly, to safeguard patient safety and integrity.
Clinical Trials - March 6, 2017
LEO Pharma announces positive clinical trial results
LEO Pharma announces positive results from a Phase 2b dose-ranging efficacy and safety study of tralokinumab in adult patients with moderate to severe atopic dermatitis (AD), a serious and chronic form of eczema. Tralokinumab is an investigational monoclonal antibody that specifically targets the cytokine IL-13,which plays an important role in the development of moderate-to-severe AD. […]
Pharma Business - October 24, 2016
LEO Pharma announces restructuring
In order to streamline operations and to facilitate the company’s entry into biologics within dermatology, LEO Pharma plans to restructure the organisation. The plans involve restructuring the global organisation and outsourcing functions, which may lead to up to 400 positions ceasing to exist within the next year. Suggested reductions are expected to affect the commercial […]
In a new job - September 14, 2016
LEO Pharma strengthens global leadership
LEO Pharma announces changes to its global leadership team. The changes are designed to strengthen LEO Pharma’s entry into biologics in dermatology. The changes come just a few months after the company signed a USD 1 billion partnership with AstraZeneca covering potential new biologic medicines for two of the world’s major skin diseases, atopic dermatitis […]
Agreement - July 2, 2016
AZ in licensing agreement with LEO Pharma
AstraZeneca has entered into an agreement with LEO Pharma A/S (LEO Pharma), a specialist in dermatology care, for the global licence to tralokinumab in skin diseases. Tralokinumab is a potential new medicine (an anti-IL-13 monoclonal antibody) that has completed a Phase IIb trial for the treatment of patients with atopic dermatitis, an inflammatory skin disease […]
